A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC

  • End date
    Jun 1, 2025
  • participants needed
  • sponsor
    Zhejiang Cancer Hospital
Updated on 25 January 2021


For most of the patients with limited-stage SCLC, thoracic radiotherapy combined with chemotherapy is the standard treatment at present. However, the optimal dose / fraction of thoracic radiotherapy for limited-stage SCLC is still in controversial.This study is designed as a prospecitive randomized non-inferiority trial.

Condition Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer Limited Stage, limited-stage small cell lung cancer
Treatment cisplatin, etoposide, Hypofractionated Radiotherapy, Hyperfractionated Radiotherapy
Clinical Study IdentifierNCT04543890
SponsorZhejiang Cancer Hospital
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 75 yrs?
Gender: Male or Female
Do you have Small Cell Lung Cancer Limited Stage?
Do you have any of these conditions: limited-stage small cell lung cancer or Small Cell Lung Cancer Limited Stage or Limited Stage Small Cell Lung Cancer?
Histologically/cytologically confirmed diagnosis of SCLC
Radiologically (including brain CT/MRI, chest and abdomen contrasted CT and bone scintigraphy. PET/CT is recommended) confirmed limited-stage
Patients should be between 18 and 75 years old
ECOG performance status of 0-1 (Karnofsky performance status 80)
With adequate cardiac, pulmonary, bone marrow, hepatic and renal function
With weight loss no more than 10% within 6 months before diagnosis
Informed consent must be signed

Exclusion Criteria

Histology confirmed the mixed NSCLC components
Other primary malignant tumors appeared within 5 years before the first administration of the study drug, except for locally curable malignant tumors after radical treatment (such as basal or squamous cell skin cancer, superficial bladder cancer or prostate, cervical or breast carcinoma in situ, etc.)
Any disease or condition contraindicated by radiotherapy or chemotherapy
Malignant pleural effusion and pericardial effusion
Pregnant and lactating women
The investigator believes that the subject's complications or other circumstances may affect the compliance with the protocol or may not be suitable for the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note